Successful canakinumab treatment identifies IL-1β as a pivotal mediator in Schnitzler syndrome
- PMID: 21704363
- DOI: 10.1016/j.jaci.2011.05.023
Successful canakinumab treatment identifies IL-1β as a pivotal mediator in Schnitzler syndrome
Comment on
-
IL-1 blockade in Schnitzler syndrome: ex vivo findings correlate with clinical remission.J Allergy Clin Immunol. 2008 Jan;121(1):260-2. doi: 10.1016/j.jaci.2007.09.021. Epub 2007 Oct 22. J Allergy Clin Immunol. 2008. PMID: 17936890 No abstract available.
-
Therapy of autoinflammatory syndromes.J Allergy Clin Immunol. 2009 Dec;124(6):1129-38; quiz 1139-40. doi: 10.1016/j.jaci.2009.11.001. J Allergy Clin Immunol. 2009. PMID: 20004774 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
